BioCryst Pharmaceuticals, Inc
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE). The company combines internal drug discovery with business development to build a pipeline of oral small molecules and injectable protein therapeutics. It has built a commercial infrastructure around ORLADEYO and uses that platform to support additional rare-disease programs. Biocryst also earns collaborative, license, service, and royalty revenue from third-party agreements, making it both a commercial-stage biotech and a development-stage pipeline company.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved pharmaceutical products sold to specialty pharmacies, distributors, hospitals, and pharmacies, primarily ORLADEYO and peramivir.
License fees, milestone payments, service revenue, and royalties from third-party collaborations and out-licensing arrangements.
Internal discovery and clinical-stage rare-disease candidates that are not yet commercial products.
Products
Reported · share of revenue- Products71.2 %
- License27.9 %
- Collaborative and Other Research and Development0.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Biocryst sells primarily into the rare-disease treatment ecosystem rather than to broad retail consumers. Its main commercial customer for ORLADEYO in the United States is a single specialty pharmacy that dispenses directly to patients, while outside the U.S. it sells through specialty distributors, hospitals, and pharmacies. The end users are patients with hereditary angioedema and other rare diseases, but purchasing and reimbursement decisions are heavily influenced by payors, specialty pharmacies, and prescribers. The company also serves pharmaceutical and biotech partners through collaboration, licensing, and royalty arrangements. Because the addressable patient populations are small, customer retention, reimbursement access, and physician adoption are especially important to revenue growth.
Buys ORLADEYO for direct-to-patient dispensing in the U.S. and is central to prescription fulfillment and revenue recognition.
Purchase ORLADEYO outside the U.S. and support market access in ex-U.S. rare-disease markets.
The end users of ORLADEYO; demand depends on diagnosis, physician prescribing, adherence, and reimbursement.
Pay for licenses, services, milestones, or royalties tied to partnered programs and out-licensed assets.
Influence adoption of ORLADEYO and other rare-disease therapies through prescribing decisions.
Strategy
Biocryst’s strategy is to use ORLADEYO as the commercial anchor while expanding into additional rare-disease opportunities. The company is emphasizing structure-guided drug design and internal discovery to generate first-in-class or best-in-class oral and injectable therapies. It also seeks to self-fund operations by increasing profitability from product sales and by monetizing assets through partnerships, royalties, and licensing. A key strategic theme is disciplined capital allocation: focusing on rare diseases where the company believes its commercial infrastructure and scientific capabilities can create durable value. The pending European ORLADEYO transaction suggests a portfolio-shaping approach that prioritizes capital efficiency and U.S.-centric commercialization.
ORLADEYO is the main revenue engine and supports the company’s commercial infrastructure.
Pipeline success is needed to diversify revenue beyond a single commercial product.
Non-dilutive funding can extend runway and reduce dependence on capital markets.
Geography
Biocryst describes itself as a global biotechnology company, but its commercial base is anchored in the United States. In the U.S., ORLADEYO is generally shipped directly to patients through a single specialty pharmacy, making U.S. market access and reimbursement especially important. Outside the U.S., the company sells through specialty distributors, hospitals, and pharmacies, so international performance depends on local distribution and payor access. The company also references a pending transaction involving the sale of its European ORLADEYO business, which could change its geographic revenue mix and reduce direct exposure to Europe. Manufacturing and third-party supply chain risk are geographically dispersed because the company relies on contract manufacturers and partners rather than a fully integrated internal manufacturing footprint.
Risks
Biocryst faces the classic risks of a commercial-stage rare-disease biotech: dependence on a small number of products, reimbursement sensitivity, and intense competition from larger pharmaceutical companies. ORLADEYO revenue depends on physician prescribing, patient retention, monthly prescription trends, and third-party payor coverage, so pricing or reimbursement pressure can quickly affect sales. The company also relies on third-party manufacturers and distributors, which creates supply, quality-control, and regulatory-compliance risk that could disrupt product availability. Because its pipeline is still being developed, clinical, regulatory, and commercialization setbacks could delay or eliminate future growth options. In addition, the company’s use of collaboration, royalty, and licensing arrangements exposes it to counterparty performance risk and uncertainty around future milestone realization.
- Dependence on ORLADEYO commercializationImpact: HighLikelihood: Medium
The company’s revenue and commercial infrastructure are heavily tied to one core HAE product.
Exposure - Reimbursement and pricing pressureImpact: HighLikelihood: Medium
Revenue from product sales depends on favorable pricing and third-party payor coverage.
Exposure: U.S. specialty pharmacy channel and ex-U.S. market access
- Clinical and regulatory failureImpact: HighLikelihood: Medium
Pipeline assets may not achieve approval or commercial viability, limiting future growth.
Exposure: Rare-disease development programs
- Manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
Biologics and pharmaceutical manufacturing are complex and rely on third parties.
Exposure - Competitive pressureImpact: MediumLikelihood: Medium
Larger competitors may launch safer, more effective, or lower-cost alternatives.
Exposure: HAE and other rare-disease markets
Accounting
Judgemental itemsReported net sales are reduced by estimated patient non-acceptances and related reversals.
Impact: Can shift revenue between quarters and affect gross-to-net visibility
Milestones, royalties, and service fees are recognized when obligations are met, not necessarily when cash is received.
Impact: Can create lumpy revenue patterns
Management has recorded a valuation allowance against substantially all tax assets due to uncertainty of future utilization.
Impact: Affects reported tax expense and effective tax rate
Similar listed companies
Publicly listed companies with a comparable business focus.
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
BioVie Inc
BIVIW · Pharmaceutical Preparations
Pharvaris N.V.
PHVS · Pharmaceutical Preparations
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Rocket Pharmaceuticals, Inc
RCKT · Pharmaceutical Preparations
Rocket Pharmaceuticals is a U.S.-based late-stage biotechnology company focused on developing genetic therapies for rare inherited diseases.
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Last updated: 24/09/2026